Sub menu

 

 

AFQLIR (Sandoz Pty Ltd)

Product name
AFQLIR
Sponsor
Sandoz Pty Ltd
Date registered
Evaluation commenced
Decision date
Approval time
200 (255 working days)
Active ingredients
Aflibercept
Registration type
New biosimilar medicine
Indication

[TRADE NAME] (aflibercept) 2 mg is indicated in adults for the treatment of:

  • neovascular (wet) age-related macular degeneration (wet AMD)
  • visual impairment due to macular oedema secondary to central retinal vein occlusion
    • (CRVO)
  • visual impairment due to macular oedema secondary to branch retinal vein occlusion (BRVO)
  • diabetic macular oedema (DME)
  • visual impairment due to myopic choroidal neovascularisation (myopic CNV).